@ eligible patients receiving stable statin ( ezetimibe ) therapy were randomized to @ of @ treatments : placebo every @ weeks ( Q@W ) or monthly ( QM ) , evolocumab @ mg or @ mg Q@W , or evolocumab @ mg or @ mg QM .